figshare
Browse
1/1
2 files

A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo

Version 2 2019-10-25, 12:19
Version 1 2018-07-12, 14:59
dataset
posted on 2019-10-25, 12:19 authored by Liam D. Cassidy, Andrew RJ. Young, Pedro A. Pérez-Mancera, Birgit Nimmervoll, Adil Jaulim, Hung-Chang Chen, Dominick J. O. McIntyre, Rebecca Brais, Thomas Ricketts, Simon Pacey, Maike De La Roche, Richard J. Gilbertson, David C. Rubinsztein, Masashi Narita

Macroautophagy/autophagy is an evolutionarily conserved catabolic pathway whose modulation has been linked to diverse disease states, including age-associated disorders. Conventional and conditional whole-body knockout mouse models of key autophagy genes display perinatal death and lethal neurotoxicity, respectively, limiting their applications for in vivo studies. Here, we have developed an inducible shRNA mouse model targeting Atg5, allowing us to dynamically inhibit autophagy in vivo, termed ATG5i mice. The lack of brain-associated shRNA expression in this model circumvents the lethal phenotypes associated with complete autophagy knockouts. We show that ATG5i mice recapitulate many of the previously described phenotypes of tissue-specific knockouts. While restoration of autophagy in the liver rescues hepatomegaly and other pathologies associated with autophagy deficiency, this coincides with the development of hepatic fibrosis. These results highlight the need to consider the potential side effects of systemic anti-autophagy therapies.

Funding

This work was supported by the University of Cambridge, Cancer Research UK and Hutchison Whampoa. The M.N., M.D.R., and R.J.G. laboratories are supported by a Cancer Research UK Cambridge Institute Core Grant [C14303/A17197]. D.C.R. was supported by Wellcome Trust Principal Research Fellowship to [095317/Z/11/Z], a Wellcome Trust Strategic Grant to Cambridge Institute for Medical Research [100140/Z/12/Z], and a UK Dementia Research Institute Professorship (funded by the MRC, Alzheimers Research UK and the Alzheimer’s Society (DCR)). A.J. is supported by a Cambridge Cancer Centre Clinical PhD research Fellowship. M.D.R. is funded by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society [107609]. M.N. is also supported by The CRUK Early Detection Pump Priming Awards [C20/A20976] and Medical Research Council [MR/M013049/1]. The CBAL is supported by an MRC grant [MRC/MC/UU/12012/5]; Cancer Research UK [C20/A20976]; Cancer Research UK [C14303/A17197]; Royal Society [107609]; Wellcome Trust [100140/Z/12/Z]; Wellcome Trust [107609]; Wellcome Trust [095317/Z/11/Z].

History

Usage metrics

    Autophagy

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC